LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Protein Biomarkers in Asthma.

    Karaulov, Alexander V / Garib, Victoria / Garib, Firuz / Valenta, Rudolf

    International archives of allergy and immunology

    2018  Volume 175, Issue 4, Page(s) 189–208

    Abstract: Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has ...

    Abstract Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has been treated for decades according to a "one-fits-all" treatment strategy based on bronchodilators and steroids. With the availability of new forms of treatment targeting the different pathomechanisms of the asthma syndrome, such as anti-immunoglobulin E and cytokine-targeting therapies, the interest in biomarkers that can dis criminate different forms of asthma according to their pathomechanisms has increased. This review attempts to provide an overview of protein biomarkers in asthma and how they might be used to discriminate different forms of asthma that may respond positively to sophisticated new targeted therapies.
    MeSH term(s) Asthma/diagnosis ; Biomarkers/analysis ; Biomarkers/metabolism ; Humans ; Proteins/analysis ; Proteins/metabolism
    Chemical Substances Biomarkers ; Proteins
    Language English
    Publishing date 2018-03-26
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1108932-5
    ISSN 1423-0097 ; 1018-2438
    ISSN (online) 1423-0097
    ISSN 1018-2438
    DOI 10.1159/000486856
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Milk of Cow and Goat, Immunized by Recombinant Protein Vaccine ZF-UZ-VAC2001(Zifivax), Contains Neutralizing Antibodies Against SARS-CoV-2 and Remains Active After Standard Milk Pasteurization.

    Garib, Victoria / Katsamaki, Stefani / Turdikulova, Shahlo / Levitskaya, Yuliya / Zahidova, Nodira / Bus, Galina / Karamova, Kristina / Rakhmedova, Manona / Magbulova, Nigora / Bruhov, Alexander / Garib, Firuz Y / Abdurakhmonov, Ibrokhim Y

    Frontiers in nutrition

    2022  Volume 9, Page(s) 901871

    Abstract: Here, we present the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cows and goat using approved recombinant protein human coronavirus vaccine, ZF-UZ-VAC2001, in ... ...

    Abstract Here, we present the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cows and goat using approved recombinant protein human coronavirus vaccine, ZF-UZ-VAC2001, in the Republic of Uzbekistan. In the period of 2 weeks after first vaccination, we detected the neutralizing antibodies against coronavirus in the blood serum of vaccinated animals. The neutralizing activity, in its peak on the 21st day after receiving the third dose (77th day from first dose), was effective in neutralization test using a live SARS-CoV-2 in Vero E6 cells, even after 120-fold serum titration. In cows receiving three dose of human vaccine, the MAGLUMI
    Language English
    Publishing date 2022-06-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2776676-7
    ISSN 2296-861X
    ISSN 2296-861X
    DOI 10.3389/fnut.2022.901871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Protein Biomarkers in Asthma

    Karaulov, Alexander V. / Garib, Victoria / Garib, Firuz / Valenta, Rudolf

    International Archives of Allergy and Immunology

    2018  Volume 175, Issue 4, Page(s) 189–208

    Abstract: Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has ...

    Institution Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation
    International Network of Universities for Molecular Allergololgy and Immunology, Vienna, Austria
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
    Department of Immunology, Russian Medical Academy of Postgraduate Continuing Education, Moscow, Russian Federation
    Department of Immunology, Lomonosov Moscow State University, Moscow, Russian Federation
    NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation
    Abstract Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has been treated for decades according to a “one-fits-all” treatment strategy based on bronchodilators and steroids. With the availability of new forms of treatment targeting the different pathomechanisms of the asthma syndrome, such as anti-immunoglobulin E and cytokine-targeting therapies, the interest in biomarkers that can dis criminate different forms of asthma according to their pathomechanisms has increased. This review attempts to provide an overview of protein biomarkers in asthma and how they might be used to discriminate different forms of asthma that may respond positively to sophisticated new targeted therapies.
    Keywords Allergy ; Biomarkers ; Asthma ; Molecular allergology
    Language English
    Publishing date 2018-03-26
    Publisher S. Karger AG
    Publishing place Basel, Switzerland
    Document type Article
    Note Review
    ZDB-ID 1108932-5
    ISSN 1423-0097 ; 1018-2438
    ISSN (online) 1423-0097
    ISSN 1018-2438
    DOI 10.1159/000486856
    Database Karger publisher's database

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.155: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Milk of cow and goat, immunized by recombinant protein vaccine ZF-UZ-VAC2001(Zifivax), contains neutralizing antibodies against SARS-CoV-2 and remains active after standard milk pasteurization

    Garib, Victoria / Katsamaki, Stefani / Turdikulova, Shahlo U. / Levitskaya, Yuliya / Zakhidova, Nodira / Bus, Galina / Karamova, Kristina / Rakhmedova, Manona / Magbulova, Nigora / Bruhov, Alexsander / Garib, Firuz Y. / Abdurakhmonov, Ibrokhim Y.

    bioRxiv

    Abstract: Here we report the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cow and goat using recombinant protein human vaccine, ZF-UZ-VAC2001. In the period of two weeks ... ...

    Abstract Here we report the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cow and goat using recombinant protein human vaccine, ZF-UZ-VAC2001. In the period of two weeks after first vaccination, we detected the neutralizing antibodies against coronavirus in the blood serum of vaccinated animals. The neutralizing activity, in its peak on the 21st days after receiving the third dose (77th day from first dose), was effective in Neutralization Test using a live SARS-CoV-2 in Vero E6 cells, even after 120-fold serum titration. Colostrum of the first day after 3rd dose vaccinated cow after calving had a greater activity to neutralize the SARS-CoV-2 compared to colostrum of subsequent three days (4.080 μ/ml vs 2.106, 1.960 and 1.126 μ/ml), goat milk (1,486 μ/ml), and cow milk (0.222 μ/ml) in MAGLUMI® SARS-CoV-2 neutralizing antibody competitive chemiluminescence immunoassay. We observed a positive correlation of receptor-binding domain (RBD)-specific IgG antibodies between the serum of actively immunized cow and milk-feeding calf during the entire course of vaccination (r = 0.95, p = 0.027). We showed an optimal regime for immune milk pasteurization at 62.5°C for 30 min, which retained specific neutralizing activity to SARS-CoV-2, potentially useful for passive immunization against coronavirus infection threats.
    Keywords covid19
    Language English
    Publishing date 2022-02-15
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2022.02.14.480298
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top